Analysts See $-0.67 EPS for Cellectis S.A. (CLLS); ONESAVINGS BANK PLC CHATHAM ORD (OSVBF) Sellers Decreased By 49.52% Their Shorts

February 18, 2018 - By Linda Rogers

Analysts expect Cellectis S.A. (NASDAQ:CLLS) to report $-0.67 EPS on March, 5.They anticipate $0.29 EPS change or 76.32% from last quarter’s $-0.38 EPS. After having $-0.73 EPS previously, Cellectis S.A.’s analysts see -8.22% EPS growth. The stock increased 0.90% or $0.29 during the last trading session, reaching $32.65. About 156,438 shares traded. Cellectis S.A. (NASDAQ:CLLS) has declined 17.09% since February 18, 2017 and is downtrending. It has underperformed by 33.79% the S&P500.

ONESAVINGS BANK PLC CHATHAM ORD (OTCMKTS:OSVBF) had a decrease of 49.52% in short interest. OSVBF’s SI was 437,500 shares in February as released by FINRA. Its down 49.52% from 866,700 shares previously. With 4,200 avg volume, 104 days are for ONESAVINGS BANK PLC CHATHAM ORD (OTCMKTS:OSVBF)’s short sellers to cover OSVBF’s short positions. It closed at $5.7 lastly. It is down 0.00% since February 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 7 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Cellectis had 13 analyst reports since April 5, 2016 according to SRatingsIntel. On Wednesday, September 6 the stock rating was maintained by Nomura with “Buy”. The stock of Cellectis S.A. (NASDAQ:CLLS) earned “Outperform” rating by Wells Fargo on Tuesday, February 28. The firm has “Buy” rating given on Wednesday, August 16 by Oppenheimer. As per Tuesday, June 6, the company rating was maintained by Jefferies. The rating was downgraded by Morgan Stanley on Monday, October 2 to “Sell”. As per Friday, June 2, the company rating was maintained by Oppenheimer. The firm has “Hold” rating given on Wednesday, September 6 by SunTrust. The firm has “Buy” rating given on Monday, September 25 by Jefferies. Jefferies maintained Cellectis S.A. (NASDAQ:CLLS) on Friday, October 27 with “Buy” rating. On Friday, October 6 the stock rating was maintained by SunTrust with “Hold”.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $1.10 billion. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

OneSavings Bank Plc operates as a specialist lender and retail savings firm in the United Kingdom and the Channel Islands. The company has market cap of $1.24 billion. The firm operates through three divisions: Buy-to-Let/SME, Residential Mortgages, and Personal Loans. It has a 9.44 P/E ratio. It offers fixed, notice, easy access, and regular savings products, including ISAs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Linda Rogers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: